Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 20/20 | 0.63 |
| ▸ | TACR2 | P21452 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14619297 | 0.91 | TACR3 (0.61) | TACR3TACR2CYP3A4 | |
| SCHEMBL4603864 | 0.89 | TACR3 (0.59) | TACR3TACR2CYP3A4 | |
| SCHEMBL4603191 | 0.89 | TACR3 (0.59) | TACR3TACR2CYP3A4 | |
| SCHEMBL4601750 | 0.89 | TACR3 (0.59) | TACR3TACR2CYP3A4 | |
| SCHEMBL4614454 | 0.89 | TACR3 (0.64) | TACR3TACR2CYP3A4 | |
| SCHEMBL14094503 | 0.86 | TACR3 (0.83) | TACR3TACR2CYP3A4 | |
| SCHEMBL4602149 | 0.84 | TACR3 (0.60) | TACR3TACR2CYP3A4 | |
| SCHEMBL5106476 | 0.83 | TACR3 (0.62) | TACR3TACR2CYP3A4 | |
| SCHEMBL4601813 | 0.82 | TACR3 (0.52) | TACR3TACR2CYP3A4 | |
| SCHEMBL5100747 | 0.82 | TACR3 (0.60) | TACR3TACR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915362-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018465-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| EP-1915362-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018465-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | NPY4R, PROKR1, NPSR1 | TACR3 41/4885TACR2 22/4885CYP3A4 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.